Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 7;5:37. doi: 10.1038/s41698-021-00175-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a KEGG enrichment of genes of which higher expression were associated with lower (left) or better (right) survival of all 2836 patients for which clinical information was available based on expression profile without any correction (log-rank test, FDR adjusted p-value < 0.05). b KEGG enrichment of genes of which higher expression were associated with lower (left) or better (right) survival of 99 patients receiving immunotherapy based on expression profile without any correction (log-rank test, FDR adjusted p-value < 0.05). c, d Pathways associated with immunotherapy-specific responses based on “mutation correction” profile (c) and “leukocyte fraction correction” profile (d). Only pathways with a statistically significant importance score after feature selection are shown here.